New Antibody-Drug combo takes aim at Hard-to-Treat ovarian cancer
NCT ID NCT06843447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload directly to them. The trial will check safety and how well the drug shrinks tumors, given alone or with other anticancer agents.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Raludotatug deruxtecan (R-DXd), an antibody-drug conjugate that targets a protein on cancer cells and delivers a chemotherapy-like payload directly to them.
What this could lead to
If this trial succeeds, it could offer a new treatment option for people with relapsed high-grade serous ovarian cancer, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early-phase trial (1b/2) with a small number of participants, so results may not apply to everyone. The drug may cause side effects like low blood counts or liver issues, and it might not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barts Health NHS Trust ( Site 0401)
RECRUITINGLondon, London, City of, E1 1RD, United Kingdom
Contact Phone: •••-•••-••••
-
Clinica Universidad de Navarra ( Site 0301)
RECRUITINGMadrid, Madrid, Comunidad de, 28027, Spain
Contact Phone: •••-•••-••••
-
Dana-Farber Cancer Institute ( Site 0015)
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
RECRUITINGMajadhonda, Madrid, 28222, Spain
Contact Phone: •••-•••-••••
-
Hospital General Universitario de Valencia ( Site 0305)
RECRUITINGValencia, Valenciana, Comunitat, 46014, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario 12 de Octubre ( Site 0304)
RECRUITINGMadrid, 28041, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
RECRUITINGMadrid, 28040, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Virgen de la Victoria ( Site 0306)
RECRUITINGMálaga, 29010, Spain
Contact Phone: •••-•••-••••
-
Houston Methodist Hospital ( Site 0010)
COMPLETEDHouston, Texas, 77030, United States
-
Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center ( Site 0003)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
OU Health University of Oklahoma Medical Center ( Site 7000)
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-••••
-
Rabin Medical Center ( Site 0203)
RECRUITINGPetah Tikva, 4941492, Israel
Contact Phone: •••-•••-••••
-
Rambam Health Care Campus ( Site 0202)
RECRUITINGHaifa, 3109601, Israel
Contact Phone: •••-•••-••••
-
Royal Marsden Hospital ( Site 0402)
RECRUITINGFulham, England, SW3 6JJ, United Kingdom
Contact Phone: •••-•••-••••
-
START Mountain Region ( Site 0008)
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Phone: •••-•••-••••
-
Shaare Zedek Medical Center ( Site 0201)
RECRUITINGJerusalem, 9103102, Israel
Contact Phone: •••-•••-••••
-
Sheba Medical Center ( Site 0200)
RECRUITINGRamat Gan, 5265601, Israel
Contact Phone: •••-•••-••••
-
Texas Oncology - DFW ( Site 8000)
RECRUITINGFort Worth, Texas, 76104, United States
Contact Phone: •••-•••-••••
-
The Christie NHS Foundation Trust ( Site 0405)
RECRUITINGManchester, M20 4BX, United Kingdom
Contact Phone: •••-•••-••••
-
The Royal Marsden NHS Foundation Trust. ( Site 0403)
RECRUITINGSutton, England, SM2 5PT, United Kingdom
Contact Phone: •••-•••-••••
-
The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
RECRUITINGLouisville, Kentucky, 40202, United States
Contact Phone: •••-•••-••••
-
University Hospitals Sussex NHS Foundation Trust ( Site 0404)
RECRUITINGBrighton, East Sussex, BN2 1ES, United Kingdom
Contact Phone: •••-•••-••••
-
University of Virginia Health System ( Site 0011)
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Phone: •••-•••-••••
-
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-••••